Abstract
Cancers result from complex evolutionary processes with selective pressure leading to the accumulation of multiple mutations in proteins involved in the signaling circuitry and basic functions of the cell. Together, the mutant gene products co-opt the cell signaling programs that maintain homeostasis in normal tissues to serve the uncontrolled proliferation, survival, angiogenesis, metabolic, and migration functions that allow cancer cells to thrive at the expense of the organism. The details of how this happens are still not entirely understood. However, intense research in the last two decades has revealed a common set of hallmark traits acquired by cells in the progression to all cancers. A seminal article by Hanahan and Weinberg in 2000 (Hanahan and Weinberg 2000) first identified six hallmarks, with an update a decade later in 2011 (Hanahan and Weinberg 2011) that provided more detailed understanding of the original hallmarks and added two emerging new ones. It also identified enabling characteristics that facilitate acquisition of the hallmarks by cancer cells. In the present chapter, we briefly summarize the hallmarks of cancer and use the Hanahan and Weinberg framework to exemplify targets in signaling pathways that lead to each of the hallmarks from a structural biology perspective. We summarize the current state of inhibitors for at least one major target protein in each of the hallmark signaling circuitry.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adams JM, Cory S (2007) Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 19:488–496
Ambrogio C, Kohler J, Zhou ZW, Wang H, Paranal R, Li J, Capelletti M, Caffarra C, Li S, Lv Q, Gondi S, Hunter JC, Lu J, Chiarle R, Santamaria D, Westover KD, Janne PA (2018) KRAS dimerization impacts MEK inhibitor sensitivity and oncogenic activity of mutant KRAS. Cell 172(857–868):e15
Araki M, Shima F, Yoshikawa Y, Muraoka S, Ijiri Y, Nagahara Y, Shirono T, Kataoka T, Tamura A (2011) Solution structure of the state 1 conformer of GTP-bound H-Ras protein and distinct dynamic properties between the state 1 and state 2 conformers. J Biol Chem 286:39644–39653
Arteaga CL (2011) ERBB receptors in cancer: signaling from the inside. Breast Cancer Res 13:304
Asai A, Oshima Y, Yamamoto Y, Uochi TA, Kusaka H, Akinaga S, Yamashita Y, Pongracz K, Pruzan R, Wunder E, Piatyszek M, Li S, Chin AC, Harley CB, Gryaznov S (2003) A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res 63:3931–3939
Autexier C, Lue NF (2006) The structure and function of telomerase reverse transcriptase. Annu Rev Biochem 75:493–517
Azemar M, Schmidt M, Arlt F, Kennel P, Brandt B, Papadimitriou A, Groner B, Wels W (2000) Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int J Cancer 86:269–275
Baerlocher GM, Burington B, Snyder DS (2015a) Telomerase inhibitor Imetelstat in essential Thrombocythemia and myelofibrosis. N Engl J Med 373:2580
Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, Spitzer G, Odenike O, Mcdevitt MA, Roth A, Daskalakis M, Burington B, Stuart M, Snyder DS (2015b) Telomerase inhibitor Imetelstat in patients with essential Thrombocythemia. N Engl J Med 373:920–928
Basilico C, Pennacchietti S, Vigna E, Chiriaco C, Arena S, Bardelli A, Valdembri D, Serini G, Michieli P (2013) Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res 19:2381–2392
Berletch JB, Liu C, Love WK, Andrews LG, Katiyar SK, Tollefsbol TO (2008) Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG. J Cell Biochem 103:509–519
Bi Y, Hao F, Yan G, Teng L, Lee RJ, Xie J (2016) Actively targeted nanoparticles for drug delivery to tumor. Curr Drug Metab 17:763–782
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915–925
Blackburn EH (2001) Switching and signaling at the telomere. Cell 106:661–673
Boriack-Sjodin PA, Margarit SM, Bar-Sagi D, Kuriyan J (1998) The structural basis of the activation of Ras by Sos. Nature 394:337–343
Bos JL, Rehmann H, Wittinghofer A (2007) GEFs and GAPs: critical elements in the control of small G proteins. Cell 129:865–877
Bryan C, Rice C, Hoffman H, Harkisheimer M, Sweeney M, Skordalakes E (2015) Structural basis of telomerase inhibition by the highly specific BIBR1532. Structure 23:1934–1942
Buhrman G, Wink G, Mattos C (2007) Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf. Structure 15:1618–1629
Buhrman G, Holzapfel G, Fetics S, Mattos C (2010) Allosteric modulation of Ras positions Q61 for a direct role in catalysis. Proc Natl Acad Sci USA 107:4931–4936
Buhrman G, O’Connor C, Zerbe B, Kearney BM, Napoleon R, Kovrigina EA, Vajda S, Kozakov D, Kovrigin EL, Mattos C (2011) Analysis of binding site hot spots on the surface of Ras GTPase. J Mol Biol 413:773–789
Burkhart DL, Sage J (2008) Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 8:671–682
Chakhparonian M, Wellinger RJ (2003) Telomere maintenance and DNA replication: how closely are these two connected? Trends Genet 19:439–446
Ciardiello F, Caputo R, Troiani T, Borriello G, Kandimalla ER, Agrawal S, Mendelsohn J, Bianco AR, Tortora G (2001) Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer 93:172–178
Collado M, Serrano M (2010) Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 10:51–57
Collins K, Mitchell JR (2002) Telomerase in the human organism. Oncogene 21:564–579
Cosentino K, Garcia-Saez AJ (2017) Bax and Bak pores: are we closing the circle? Trends Cell Biol 27:266–275
Cragg MS, Harris C, Strasser A, Scott CL (2009) Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer 9:321–326
Cristofari G, Lingner J (2003) Fingering the ends: how to make new telomeres. Cell 113:552–554
Cui JJ, Tran-Dube M, Shen H, Nambu M, Kung PP, Pairish M, Jia L, Meng J, Funk L, Botrous I, Mctigue M, Grodsky N, Ryan K, Padrique E, Alton G, Timofeevski S, Yamazaki S, Li Q, Zou H, Christensen J, Mroczkowski B, Bender S, Kania RS, Edwards MP (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 54:6342–6363
Czabotar PE, Lee EF, Van Delft MF, Day CL, Smith BJ, Huang DC, Fairlie WD, Hinds MG, Colman PM (2007) Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci USA 104:6217–6222
Day PJ, Cleasby A, Tickle IJ, O'reilly M, Coyle JE, Holding FP, Mcmenamin RL, Yon J, Chopra R, Lengauer C, Jhoti H (2009) Crystal structure of human CDK4 in complex with a D-type cyclin. Proc Natl Acad Sci USA 106:4166–4170
Delbridge AR, Strasser A (2015) The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ 22:1071–1080
Dong CK, Masutomi K, Hahn WC (2005) Telomerase: regulation, function and transformation. Crit Rev Oncol Hematol 54:85–93
Dyson NJ (2016) RB1: a prototype tumor suppressor and an enigma. Genes Dev 30:1492–1502
Eathiraj S, Palma R, Volckova E, Hirschi M, France DS, Ashwell MA, Chan TC (2011) Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem 286:20666–20676
Echalier A, Endicott JA, Noble ME (2010) Recent developments in cyclin-dependent kinase biochemical and structural studies. Biochim Biophys Acta 1804:511–519
Eder JP, Vande Woude GF, Boerner SA, Lorusso PM (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15:2207–2214
Endres NF, Engel K, Das R, Kovacs E, Kuriyan J (2011) Regulation of the catalytic activity of the EGF receptor. Curr Opin Struct Biol 21:777–784
Evans LM, Cowey SL, Siegal GP, Hardy RW (2009) Stearate preferentially induces apoptosis in human breast cancer cells. Nutr Cancer 61:746–753
Fattore L, Marra E, Pisanu ME, Noto A, De Vitis C, Belleudi F, Aurisicchio L, Mancini R, Torrisi MR, Ascierto PA, Ciliberto G (2013) Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. J Transl Med 11:180
Ferguson KM (2008) Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys 37:353–373
Fetics SK, Guterres H, Kearney BM, Buhrman G, Ma B, Nussinov R, Mattos C (2015) Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD. Structure 23:505–516
Franco AT, Corken A, Ware J (2015) Platelets at the interface of thrombosis, inflammation, and cancer. Blood 126:582–588
Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:1427–1438
Fuh G, Li B, Crowley C, Cunningham B, Wells JA (1998) Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J Biol Chem 273:11197–11204
Garrett TP, Mckern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, Jorissen RN, Nice EC, Burgess AW, Ward CW (2002) Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110:763–773
Gentile DR, Rathinaswamy MK, Jenkins ML, Moss SM, Siempelkamp BD, Renslo AR, Burke JE, Shokat KM (2017) Ras binder induces a modified switch-II pocket in GTP and GDP states. Cell Chem Biol 24(1455–1466):e14
Ghobrial IM, Witzig TE, Adjei AA (2005) Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55:178–194
Gillis AJ, Schuller AP, Skordalakes E (2008) Structure of the Tribolium castaneum telomerase catalytic subunit TERT. Nature 455:633–637
Gorfe AA, Hanzal-Bayer M, Abankwa D, Hancock JF, Mccammon JA (2007) Structure and dynamics of the full-length lipid-modified H-Ras protein in a 1,2-dimyristoylglycero-3-phosphocholine bilayer. J Med Chem 50:674–684
Gorfe AA, Grant BJ, Mccammon JA (2008) Mapping the nucleotide and isoform-dependent structural and dynamical features of Ras proteins. Structure 16:885–896
Goyal L, Muzumdar MD, Zhu AX (2013) Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res 19:2310–2318
Haigis KM (2017) KRAS alleles: the devil is in the detail. Trends Cancer 3:686–697
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674
Harari PM (2004) Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11:689–708
Harkisheimer M, Mason M, Shuvaeva E, Skordalakes E (2013) A motif in the vertebrate telomerase N-terminal linker of TERT contributes to RNA binding and telomerase activity and processivity. Structure 21:1870–1878
Headley MB, Bins A, Nip A, Roberts EW, Looney MR, Gerard A, Krummel MF (2016) Visualization of immediate immune responses to pioneer metastatic cells in the lung. Nature 531:513–517
Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA (2004) Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56:549–580
Hoffman H, Rice C, Skordalakes E (2017) Structural analysis reveals the deleterious effects of telomerase mutations in bone marrow failure syndromes. J Biol Chem 292:4593–4601
Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS (2002) VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99:11393–11398
Houtgraaf JH, Versmissen J, Van Der Giessen WJ (2006) A concise review of DNA damage checkpoints and repair in mammalian cells. Cardiovasc Revasc Med 7:165–172
Jacobs SA, Podell ER, Cech TR (2006) Crystal structure of the essential N-terminal domain of telomerase reverse transcriptase. Nat Struct Mol Biol 13:218–225
Jager K, Walter M (2016) Therapeutic targeting of telomerase. Genes (Basel) 7
Jiang Y, Xu W, Lu J, He F, Yang X (2001) Invasiveness of hepatocellular carcinoma cell lines: contribution of hepatocyte growth factor, c-met, and transcription factor Ets-1. Biochem Biophys Res Commun 286:1123–1130
John J, Frech M, Wittinghofer A (1988) Biochemical properties of Ha-ras encoded p21 mutants and mechanism of the autophosphorylation reaction. J Biol Chem 263:11792–11799
Johnson CW, Mattos C (2013) The allosteric switch and conformational states in Ras GTPase affected by small molecules. Enzymes 33 Pt A:41–67
Johnson CW, Reid D, Parker JA, Salter S, Knihtila R, Kuzmic P, Mattos C (2017) The small GTPases K-Ras, N-Ras, and H-Ras have distinct biochemical properties determined by allosteric effects. J Biol Chem 292:12981–12993
Johnson CW, Lin Y-J, Reid D, Parker J, Pavlopoulos S, Dischinger P, Graveel C, Aguirre AJ, Steensma M, Haigis KM, Mattos C (2019) Isoform-specific destabilization of the active site reveals molecular mechanism of intrinsic activation of KRas G13D. Cell Rep 28(6):1538–1550
Kalra S, Joshi G, Munshi A, Kumar R (2017) Structural insights of cyclin dependent kinases: implications in design of selective inhibitors. Eur J Med Chem 142:424–458
Karagonlar ZF, Korhan P, Atabey N (2015) Targeting c-met in cancer by MicroRNAs: potential therapeutic applications in hepatocellular carcinoma. Drug Dev Res 76:357–367
Kauke MJ, Traxlmayr MW, Parker JA, Kiefer JD, Knihtila R, Mcgee J, Verdine G, Mattos C, Wittrup KD (2017) An engineered protein antagonist of K-Ras/B-Raf interaction. Sci Rep 7:5831
Kelleher C, Teixeira MT, Forstemann K, Lingner J (2002) Telomerase: biochemical considerations for enzyme and substrate. Trends Biochem Sci 27:572–579
Khan KH, Blanco-Codesido M, Molife LR (2014) Cancer therapeutics: targeting the apoptotic pathway. Crit Rev Oncol Hematol 90:200–219
Koff JL, Ramachandiran S, Bernal-Mizrachi L (2015) A time to kill: targeting apoptosis in cancer. Int J Mol Sci 16:2942–2955
Kopp HG, Placke T, Salih HR (2009) Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 69:7775–7783
Lambert AW, Pattabiraman DR, Weinberg RA (2017) Emerging biological principles of metastasis. Cell 168:670–691
Lee EF, Czabotar PE, Smith BJ, Deshayes K, Zobel K, Colman PM, Fairlie WD (2007) Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ 14:1711–1713
Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141:1117–1134
Li T, Weng T, Zuo M, Wei Z, Chen M, Li Z (2016) Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents. Future Med Chem 8(17):2047–2076
Lingner J, Cooper JP, Cech TR (1995) Telomerase and DNA end replication: no longer a lagging strand problem? Science 269:1533–1534
Lowe M, Lane JD, Woodman PG, Allan VJ (2004) Caspase-mediated cleavage of syntaxin 5 and giantin accompanies inhibition of secretory traffic during apoptosis. J Cell Sci 117:1139–1150
Lu H, Schulze-Gahmen U (2006) Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition. J Med Chem 49:3826–3831
Lue NF, Lin YC, Mian IS (2003) A conserved telomerase motif within the catalytic domain of telomerase reverse transcriptase is specifically required for repeat addition processivity. Mol Cell Biol 23:8440–8449
Mackenzie SH, Clark AC (2012) Death by caspase dimerization. Adv Exp Med Biol 747:55–73
Malumbres M (2014) Cyclin-dependent kinases. Genome Biol 15:122
Marcus K, Mattos C (2015) Direct attack on RAS: intramolecular communication and mutation-specific effects. Clin Cancer Res 21:1810–1818
Matsumoto M, Nakajima W, Seike M, Gemma A, Tanaka N (2016) Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells. Biochem Biophys Res Commun 473:490–496
Mctigue M, Murray BW, Chen JH, Deng YL, Solowiej J, Kania RS (2012) Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proc Natl Acad Sci USA 109:18281–18289
Meadows KL, Hurwitz HI (2012) Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2
Micalizzi DS, Farabaugh SM, Ford HL (2010) Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 15:117–134
Mitchell M, Gillis A, Futahashi M, Fujiwara H, Skordalakes E (2010) Structural basis for telomerase catalytic subunit TERT binding to RNA template and telomeric DNA. Nat Struct Mol Biol 17:513–518
Mok TS (2011) Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol 8:661–668
Morgan DO (1997) Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13:261–291
Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS, Nettesheim D, Chang BS, Thompson CB, Wong SL, Ng SL, Fesik SW (1996) X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381:335–341
Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, De Vos AM (1997) Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci USA 94:7192–7197
Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB, De Vos AM (1998) VEGF and the fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 6:1153–1167
Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, Hill J, Moussa MM, Leggett DS, Li CJ (2010) ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 9:1544–1553
Neal SE, Eccleston JF, Hall A, Webb MR (1988) Kinetic analysis of the hydrolysis of GTP by p21N-ras. The basal GTPase mechanism. J Biol Chem 263:19718–19722
Nguyen THD, Tam J, Wu RA, Greber BJ, Toso D, Nogales E, Collins K (2018) Cryo-EM structure of substrate-bound human telomerase holoenzyme. Nature 557:190–195
Nussinov R, Tsai CJ, Mattos C (2013) ‘Pathway drug cocktail’: targeting Ras signaling based on structural pathways. Trends Mol Med 19:695–704
Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110:775–787
Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O’connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677–681
Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM (2013) K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503:548–551
Pacold ME, Suire S, Perisic O, Lara-Gonzalez S, Davis CT, Walker EH, Hawkins PT, Stephens L, Eccleston JF, Williams RL (2000) Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 103:931–943
Pai EF, Krengel U, Petsko GA, Goody RS, Kabsch W, Wittinghofer A (1990) Refined crystal structure of the triphosphate conformation of H-ras p21 at 1.35 A resolution: implications for the mechanism of GTP hydrolysis. EMBO J 9:2351–2359
Parast CV, Mroczkowski B, Pinko C, Misialek S, Khambatta G, Appelt K (1998) Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis. Biochemistry 37:16788–16801
Parker JA, Mattos C (2015) The Ras-membrane Interface: isoform-specific differences in the catalytic domain. Mol Cancer Res 13:595–603
Parker MW, Pattus F (1993) Rendering a membrane protein soluble in water: a common packing motif in bacterial protein toxins. Trends Biochem Sci 18:391–395
Parker JA, Volmar AY, Pavlopoulos S, Mattos C (2018) K-Ras populates conformational states differently from its isoform H-Ras and oncogenic mutant K-RasG12D. Structure 26:810
Polo SE, Jackson SP (2011) Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev 25:409–433
Ponzetto C, Bardelli A, Zhen Z, Maina F, Dalla Zonca P, Giordano S, Graziani A, Panayotou G, Comoglio PM (1994) A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77:261–271
Prior IA, Lewis PD, Mattos C (2012) A comprehensive survey of Ras mutations in cancer. Cancer Res 72:2457–2467
Qi XS, Guo XZ, Han GH, Li HY, Chen J (2015) MET inhibitors for treatment of advanced hepatocellular carcinoma: A review. World J Gastroenterol 21:5445–5453
Raimondi F, Orozco M, Fanelli F (2010) Deciphering the deformation modes associated with function retention and specialization in members of the Ras superfamily. Structure 18:402–414
Rajabi M, Mousa SA (2017) The role of angiogenesis in Cancer treatment. Biomedicine 5
Reddy EP, Reynolds RK, Santos E, Barbacid M (1982) A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300:149–152
Reed JC (1994) Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1–6
Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, Lopez Lopez C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J (2018) Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol 19:682–693
Roskoski R Jr (2008) VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem Biophys Res Commun 375:287–291
Roskoski R Jr (2015) A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res 100:1–23
Russo AA, Jeffrey PD, Pavletich NP (1996) Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat Struct Biol 3:696–700
Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F, Wittinghofer A (1997) The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277:333–338
Schneider MR, Wolf E (2009) The epidermal growth factor receptor ligands at a glance. J Cell Physiol 218:460–466
Schulze-Gahmen U, De Bondt HL, Kim SH (1996) High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design. J Med Chem 39:4540–4546
Scorrano L, Korsmeyer SJ (2003) Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun 304:437–444
Shay JW, Wright WE (2002) Telomerase: a target for cancer therapeutics. Cancer Cell 2:257–265
Shibue T, Weinberg RA (2017) EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol 14:611–629
Sicheri F, Kuriyan J (1997) Structures of Src-family tyrosine kinases. Curr Opin Struct Biol 7:777–785
Singh M, Wang Z, Koo BK, Patel A, Cascio D, Collins K, Feigon J (2012) Structural basis for telomerase RNA recognition and RNP assembly by the holoenzyme La family protein p65. Mol Cell 47:16–26
Smogorzewska A, De Lange T (2004) Regulation of telomerase by telomeric proteins. Annu Rev Biochem 73:177–208
Spencer-Smith R, Koide A, Zhou Y, Eguchi RR, Sha F, Gajwani P, Santana D, Gupta A, Jacobs M, Herrero-Garcia E, Cobbert J, Lavoie H, Smith M, Rajakulendran T, Dowdell E, Okur MN, Dementieva I, Sicheri F, Therrien M, Hancock JF, Ikura M, Koide S, O'bryan JP (2017) Inhibition of RAS function through targeting an allosteric regulatory site. Nat Chem Biol 13:62–68
Spoerner M, Herrmann C, Vetter IR, Kalbitzer HR, Wittinghofer A (2001) Dynamic properties of the Ras switch I region and its importance for binding to effectors. Proc Natl Acad Sci USA 98:4944–4949
Stamos J, Sliwkowski MX, Eigenbrot C (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277:46265–46272
Stamos J, Lazarus RA, Yao X, Kirchhofer D, Wiesmann C (2004) Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. EMBO J 23:2325–2335
Stieglitz B, Bee C, Schwarz D, Yildiz O, Moshnikova A, Khokhlatchev A, Herrmann C (2008) Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II. EMBO J 27:1995–2005
Sun W, Yang J (2010) Functional mechanisms for human tumor suppressors. J Cancer 1:136–140
Sun Q, Burke JP, Phan J, Burns MC, Olejniczak ET, Waterson AG, Lee T, Rossanese OW, Fesik SW (2012) Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl 51:6140–6143
Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM, Laborde RR, Wassie E, Schimek L, Hanson CA, Gangat N, Wang X, Pardanani A (2015) A pilot study of the telomerase inhibitor Imetelstat for myelofibrosis. N Engl J Med 373:908–919
Torok S, Rezeli M, Kelemen O, Vegvari A, Watanabe K, Sugihara Y, Tisza A, Marton T, Kovacs I, Tovari J, Laszlo V, Helbich TH, Hegedus B, Klikovits T, Hoda MA, Klepetko W, Paku S, Marko-Varga G, Dome B (2017) Limited tumor tissue drug penetration contributes to primary resistance against angiogenesis inhibitors. Theranostics 7:400–412
Trusolino L, Bertotti A, Comoglio PM (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11:834–848
Vermeulen K, Van Bockstaele DR, Berneman ZN (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36:131–149
Vetter IR, Wittinghofer A (2001) The guanine nucleotide-binding switch in three dimensions. Science 294:1299–1304
Von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Muller BM, Denkert C, Loibl S, Nekljudova V, Untch M (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366:299–309
Wang Y, Zhang H, Gigant B, Yu Y, Wu Y, Chen X, Lai Q, Yang Z, Chen Q, Yang J (2016) Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery. FEBS J 283:102–111
Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81:323–330
Welburn JPI, Jeyaprakash AA (2018) Mechanisms of mitotic kinase regulation: a structural perspective. Front Cell Dev Biol 6:6
Welti J, Loges S, Dimmeler S, Carmeliet P (2013) Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 123:3190–3200
White LK, Wright WE, Shay JW (2001) Telomerase inhibitors. Trends Biotechnol 19:114–120
Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA, De Vos AM (1997) Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 91:695–704
Wyatt HD, West SC, Beattie TL (2010) InTERTpreting telomerase structure and function. Nucleic Acids Res 38:5609–5622
Yamazaki H, Kijima H, Ohnishi Y, Abe Y, Oshika Y, Tsuchida T, Tokunaga T, Tsugu A, Ueyama Y, Tamaoki N, Nakamura M (1998) Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. J Natl Cancer Inst 90:581–587
Yan N, Shi Y (2005) Mechanisms of apoptosis through structural biology. Annu Rev Cell Dev Biol 21:35–56
Yewale C, Baradia D, Vhora I, Patil S, Misra A (2013) Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials 34:8690–8707
Yin XM, Oltvai ZN, Korsmeyer SJ (1994) BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369:321–323
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Reid, D., Mattos, C. (2019). Targeting Cancer from a Structural Biology Perspective. In: Bose, K., Chaudhari, P. (eds) Unravelling Cancer Signaling Pathways: A Multidisciplinary Approach. Springer, Singapore. https://doi.org/10.1007/978-981-32-9816-3_12
Download citation
DOI: https://doi.org/10.1007/978-981-32-9816-3_12
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-32-9815-6
Online ISBN: 978-981-32-9816-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)